NHLBI stops trial of estrogen plus progestin due to increased breast cancer risk and lack of overall benefit.
D001943:Breast Neoplasms / Q000139:chemically induced*; D002986:Clinical Trials as Topic; D004338:Drug Combinations; D004967:Estrogens / Q000009:adverse effects* / Q000627:therapeutic use*; D005260:Female; D006331:Heart Diseases / Q000517:prevention & control*; D006801:Humans; D009316:National Institutes of Health (U.S.); D011372:Progestins / Q000009:adverse effects* / Q000627:therapeutic use*; D018570:Risk Assessment; D014481:United States
D004338:Drug Combinations; D004967:Estrogens; D011372:Progestins